U.S. MarketsSeptember 28 at 08:01 AM

US FDA Approves AbbVie's (ABBV) JUVMO (tavapadon) for Parkinson's disease

StockNow breaking-news AI analysis

The FDA approved AbbVie's JUVMO (tavapadon) for Parkinson's disease, supporting the company's projected $5 billion-plus peak sales potential across its Parkinson's franchise alongside Vyalev and Duopa.

1 stocks

ABBVABBVIE INC.$264.35Current price

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

Geopolitics

US official involved in Iran talks says Trump wants a permanent deal with full terms, Al Arabiya reports

Geopolitics

Iranian President Pezeshkian says Iran remains ready for dialogue despite being attacked during previous talks, but pressure and attacks will not force Iran to surrender

U.S. Markets

Nvidia's (NVDA) Board of Directors has authorized a USD 150bln increase to the share repurchase program, raising the remaining total program to USD 235bln

NVDA